• Explore /
  • Poster
  • / Sorafenib (Soraf) and irinotecan (Iri) combination for pretreated RAS-mutated metastatic colorectal cancer (mCRC) patients: A multicentre randomized phase II trial (NEXIRI 2-PRODIGE 27).

Sorafenib (Soraf) and irinotecan (Iri) combination for pretreated RAS-mutated metastatic colorectal cancer (mCRC) patients: A multicentre randomized phase II trial (NEXIRI 2-PRODIGE 27).

Abstract Poster

Authors

null

Emmanuelle Samalin

Institut régional du Cancer de Montpellier (ICM), Montpellier, France

Emmanuelle Samalin , Christelle De La Fouchardiere , Simon Thezenas , Valerie Boige , Helene Senellart , Rosine Guimbaud , Julien Taïeb , Eric Francois , Marie-Pierre Galais , Antoine Adenis , Astrid Lievre , Jean-François Seitz , Jean-Philippe Metges , Frédéric Di Fiore , Florence Boissiere , Evelyne Lopez-Crapez , Frederic Bibeau , Alexandre Ho-Pun-Cheung , Thibault Mazard , Marc Ychou

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT01715441

Citation

J Clin Oncol 34, 2016 (suppl; abstr 3545)

DOI

10.1200/JCO.2016.34.15_suppl.3545

Abstract #

3545

Poster Bd #

242

Abstract Disclosures

Similar Posters

First Author: Emmanuelle Samalin

First Author: Hirokazu Shoji

First Author: Kazuhisa Yamaguchi

First Author: Nicolas Huyghe